Merck & Company, Inc.

Analyst Ratings Synthesis

The consensus is Buy across 24 analysts. Price targets cluster around a $156 mean, with a $161 low and $172 high, creating an $11 spread between the stated low and high; the mean is $11 above the low and $16 below the high. The supplied evidence does not identify which named analyst or firm is most bullish or least bullish. It also provides no attributable target revisions during the past week, so a revision direction cannot be established. The substantive disagreement is valuation versus execution: bullish views appear to rely on Keytruda’s trial expansion, the pipeline, and earnings capacity, while more cautious views emphasize limited revenue-growth change, possible dividend-sustainability pressure, and valuation estimates describing the shares as overvalued.